

YEAR-END REPORT JANUARY-DECEMBER 2015

Financial overview

	October-December		January-December	
	2015	2014	2015	2014
Net sales	3,499	2,099	13,268	8,252
Other operating income	4,030	363	9,255	1,782
Expenses for the period ¹⁾	(10,702)	(8,628)	(42,347)	(30,505)
Gross profit/loss	(137)	(2,096)	(1,429)	(5,979)
EBITDA	(2,858)	(5,781)	(14,775)	(19,197)
Operating profit/loss	(3,173)	(6,166)	(19,824)	(20,471)
Comprehensive income for the period	(3,104)	(7,861)	(19,928)	(22,049)
Comprehensive income per share ²⁾	(0.08)	(0.36)	(0.66)	(1.02)
Cash flow from operating activities	(3,940)	(5,676)	(16,117)	(22,193)
Cash and cash equivalents, including short-term investments at end of period	2,052	5,688	2,052	5,688

1) Includes non-recurrent expenses of SEK 6m for the full year 2015.

2) Based on a weighted average of the number of outstanding shares (basic and diluted)

Summary: fourth quarter 2015

- **Net sales** rose by about 67 percent to SEK 3,499k (2,099k).
- **Gross profit/loss** improved by SEK 1,959 to SEK –137k (loss: 2,096k).
- **Gross margin** improved, 74 percent in 2015, compared with 63 percent in 2014.
- **Profit/loss after tax** improved by SEK 4,799k to SEK -3,062k (loss: 7,861k).
- **Comprehensive income** improved by SEK 4,757 to SEK -3,104k (loss: 7,861k).
- **Comprehensive income per share** totaled SEK -0.08 (-0.36).
- **Cash flow** from operating activities was SEK -3,940k (-5,676k).
- **GingisKHAN™ Fab kit**, Genovis launched a further development of the product GingisKHAN™ that will be marketed under the name GingisKHAN™ Fab kit.

Summary: full-year 2015

- **Net sales** improved by about 61% to SEK 13,268k (8,252k).
- **Gross profit/loss** improved by SEK 4,550k to SEK -1,429k (loss: 5,979k).
- **Gross margin** improved, 82 percent in 2015, compared with 58 percent in 2014.
- **Profit/loss after tax** improved by SEK 2,143k to SEK -19,906 (loss: 22,049). Non-recurring expenses had a negative impact on earnings of SEK 6,071k.
- **Comprehensive income** improved by SEK 2,121k to SEK -19,928k (loss: 22,049).
- **Comprehensive income per share** totaled SEK -0.66 (-1.02).
- **Cash flow** from operating activities was SEK -16,117k (-22,193).
- **Genovis reorganized**, discontinued operations in the subsidiary GeccoDots and sold the intellectual property rights behind the Nanomotus project to the inventors against future royalties.

COMMENTS FROM FREDRIK OLSSON, CEO

In early 2014 we decided to change our marketing and sales strategy and shift completely to direct sales with our own organization in the most important markets. In 2015 we were able to fully implement this decision. The effect is clear: we increased sales for the full year by more than 60 percent to SEK 13.3 million. Direct contact with the end customer is a strong contributing factor for growth in each quarter of 2015 compared with 2014.

We streamlined operations during the year to focus on products based on our unique enzymes, which are principally used in the biopharma industry. The restructuring process had a negative impact on twelve-month earnings of about SEK 6 million, attributable to impairment losses and personnel costs. We are now entering 2016 with a cost-effective organization that is adapted for growth.

Our gross margin improved significantly during the year: 82 percent in 2015, compared with 58 percent in 2014. Our production is now efficient and scalable to be able to meet increased demand.

In the fourth quarter of 2015 our sales surged by 67 percent compared with the corresponding period in 2014. Exchange rate effects in this context are marginal (approximately 7 percent), which means we are growing organically – and this is important for Genovis' employees, as well as for our shareholders. This achievement reaffirms our conviction to follow and further strengthen our sales strategy in 2016.

Genovis develops and sells products that meet the current and future needs of our customers. In order to continue doing what is necessary, we need not only innovative and talented employees, but also the resources to further strengthen the marketing organization. We intend to further expand our marketing campaigns in 2016 by strengthening existing markets with more resources to drive sales even stronger. We will also seek a local presence in markets where we see significant potential, especially in Asia. We also plan to launch products for new markets and applications to drive growth further during the year. My assessment is that these initiatives will double sales within 18 months and create an organization that can handle continued rapid growth.

Genovis has always had a clear strategy in which interaction with customers guides how we conduct business –

every day! This strategy applies to our products, customer care, support and delivery, as well as the simplicity of ordering our products. Our main focus is to solve challenges for our customers in a better way than our competitors do and I am convinced that we have the right strategy to optimally increase value for Genovis shareholders moving forward.

THE GENOVIS GROUP

Products

**FabRICATOR® (IdeS), FabRICATOR®Z (IdeZ), GingisKHAN™ (KGP), FabULOUS® (SpeB)
IgGZERO® (EndoS), GlycINATOR® (EndoS2)**

FabRICATOR is a unique enzyme that cleaves antibodies into two parts: a F(ab')₂ fragment and an Fc fragment, with extremely high precision and FabRICATOR®Z also cleaves a specific type of mouse IgG quickly and more effectively than FabRICATOR and the other enzymes on the market. FabULOUS is an enzyme that cleaves an antibody into three parts. The product is a complement to FabRICATOR. By using the two products together, the customer gets a fast method to characterize the "hinge region" of an antibody, which is important in many antibody drug conjugate (ADC) drug candidates. IgGZERO is a protein that can specifically cleave sugar molecules that are found naturally on antibodies for "glycan analysis." GlycINATOR is another enzyme that can rapidly cleave sugar molecules from an antibody. By using IgGZERO in combination with GlycINATOR it is possible to carry out a relatively simple quantitative analysis of high-mannose molecules on antibodies. Mannose is a particularly important parameter to understand and handle when developing production processes for antibody-based drugs. GingisKHAN™ is an enzyme that cleaves human antibodies into three parts. The product complements FabRICATOR® and FabULOUS®, but can also be used in studies of the different parts of the antibody separately, which makes the product unique.

Customers use the products in recurring processes. In addition to the actual product, Genovis provides global deliveries and support within 24 hours. During product development, Genovis places great emphasis on ensuring that the customer experience is as positive as possible, which means that the products must be robust, easy to use and stable during shipping and storage. Standardized formats, clear instructions and close customer relationships are key elements to ensure that the product works as intended, even for inexperienced customers. The products can be ordered from a standard product line or adapted to the needs of the customer. Customers use the products to screen new drug substances and for quality control in development and production of new antibody-based drugs.

Sales

Net sales

Net sales for the full year rose to SEK 13,268k (8,252k), an increase of 61 percent compared with the same period in 2014. Net sales for the fourth quarter rose to SEK 3,499k (2,099k), an increase in sales of 67 percent compared with 2014.

Other operating income

Other operating income for the full year amounted to SEK 9,255k (1,782k) and during fourth quarter SEK 4,030k (363k). Revenue largely comprises an insurance reimbursement related to the ongoing patent dispute in the US.

Revenue by geographic area (SEK thousands)

	October-December		January-December	
	2015	2014	2015	2014
Europe	1,478	1,041	4,165	3,135
North America	1,764	939	8,479	4,841
Other countries	257	119	624	276
Total	3,499	2,099	13,268	8,252

Performance

Gross profit/loss

Consolidated gross loss for the full year was SEK -1,429k (loss: -5,979k) and for the fourth quarter SEK -137k (loss: 2,096k). Increased revenue for the Group as well as reduced costs resulting from the winding up of the subsidiary GeccoDots contributed to the improved performance.

Financial income and expenses

Net financial expenses and income for the full year amounted to SEK -34k (140k) and for the fourth quarter SEK 0 (23k).

Profit/loss after tax

Consolidated loss after tax for the full year was SEK 19,906k (loss: 22,049k), of which the loss for the fourth quarter was

SEK 3,062k (loss: -7,861k). Non-recurrent expenses of SEK 6 million resulting from the winding up of the subsidiary GeccoDots had a negative impact on earnings.

Comprehensive income for the full year was a loss of SEK 19,928k (loss: 22,049k), of which the fourth quarter accounted for a loss of SEK 3,104k (loss: -7,861k)

Expenses

Consolidated expenses for the year increased by SEK 11,842k to SEK 42,347k (30,505k). Operating expenses are allocated as follows: raw materials and consumables SEK 2,459k (3,430k) and other external expenses 21,493k (12,583k). The increase in other external expenses is largely attributable to attorney fees in connection with the lawsuit against Promega, where the majority of expenses are covered by Genovis' insurance. Personnel costs totaled SEK 13,346k (13,186k), of which SEK 2,172k relates to non-recurrent expenses attributable to the restructuring and winding up of GeccoDots, which was completed in the third quarter.

Total expenses for the fourth quarter were SEK 10,702k (8,628k). Operating expenses are allocated as follows: raw materials and consumables SEK 895k (771k), other external expenses SEK 6,771k (3,787k) and personnel costs SEK 2,853k (3,688k).

Investments

Consolidated capital expenditure for the full year totaled SEK 1,686k (3,043k) of which SEK 189k (1,240k) is attributable to property, plant, and equipment, primarily laboratory equipment/computers and SEK 1,497k (1,803k) is attributable to investments in intangible fixed assets. Consolidated capital expenditure during the fourth quarter totaled SEK 153k (865k) of which SEK 80k (397k) is attributable to property, plant, and equipment, and SEK 73k (468k) is attributable to investments in intangible fixed assets.

Cash Flow

Consolidated cash flow for the full year totaled SEK 1,364k (208k). Cash flow from financing activities totaled SEK 14,167k (27,444k) and is attributable to the rights issues in 2014 and 2015.

Cash flow for the fourth quarter was SEK -4,093k (-6,315k). Cash flow from financing activities totaled SEK 0 (226k).

Financial position

Consolidated cash and cash equivalents including short-term investments amounted to SEK 2,052k (5,688k) at year-end. The available working capital is not sufficient to run the Company over the upcoming twelve-month period, but the Board of Directors believes it is possible to raise the capital required in addition to the expected revenues through the authorization to issue new shares as resolved by the Annual General Meeting on May 5, 2015.

The Company does not have any interest-bearing liabilities.

Total shareholders' equity for the Group was SEK 8,822 after taking the net loss for the year into account. Earnings per share for the full year, based on a weighted average of the number of outstanding shares, totaled SEK -0.66 (-1.02), with SEK -0.09 (-0.36) for the fourth quarter. The Group's equity ratio at year-end was 52 (75) percent and equity per share was SEK 0.29 (0.68), based on the fully diluted average number of shares.

Taxes

The Group has a deferred tax asset that arises from the Parent Company, amounting to SEK 1,718k (1,718k) at year-end.

Employees

On December 31, 2015, the Group had thirteen employees, compared with 2014, when the Group had sixteen employees. All employees are employed by the Parent Company.

Share capital and Share Performance

Share capital at the end of the period amounted to SEK 9,215,693.75. The total number of shares was 36,862,775 with a par value of SEK 0.25. The Company has issued 450,000 warrants subscribed to by CEO Fredrik Olsson and Chairman of the Board Sarah Fredriksson.

Genovis shares are traded on NASDAQ Stockholm First North under the ticker symbol GENO. First North is an alternative market, operated by the various exchanges within Nasdaq OMX. Companies on First North are subject to the rules of First North and not the legal requirements for admission to trading on a regulated market. The Company's Certified Adviser is Consensus, tel: +46 (0)31-745 50 00.

PARENT COMPANY GENOVIS AB

Net sales and operating profit/loss in the Parent Company are attributable to the primary and only business area: product sales and/or outlicensing of research-based innovations. According to Genovis, the company does not meet the definition of geographical areas under IAS 14 and therefore no secondary segment information is provided.

Revenue

Revenue for the full year totaled SEK 21,525k (12,005k). SEK 10,795k (8,159k) was attributable to revenue from external sales and SEK 10,730k (3,846k) to other revenue. Revenue for the fourth quarter was SEK 6,988k (3,118k), of which SEK 2,941k (2,080k) was attributable to revenue from sales and SEK 4,047k (1,038k) to other revenue. Other revenue largely comprises insurance reimbursement in connection with the ongoing patent dispute in the US.

Expenses

Total operating costs for the full year amounted to SEK 39,195k (26,848k), including non-recurrent expenses of SEK 6,576. Expenses for the fourth quarter totaled SEK 9,895k (7,773k). The non-recurrent expenses relate to increased personnel costs, impairment of patents and amortization of debt on the subsidiary as a result of the restructuring and winding up of GeccoDots, which was completed during the third quarter.

In addition to non-recurrent expenses for restructuring, other external expenses are largely attributable to attorney fees in connection with the lawsuit against Promega, where the majority of expenses are covered by Genovis' insurance.

Performance

Operating loss for full-year 2015 was SEK 17,670k (loss: 14,843k) and loss after net financial items was SEK 20,000k (loss: 20,288k). Loss for the full year period was SEK 20,000k (loss: 22,006k). Operating loss for the fourth quarter improved to SEK 2,907k (loss: 4,655k) and loss after net financial items was SEK 2,907k (loss:

6,118k). Loss for the fourth quarter period improved by SEK 4,929k to SEK 2,907k (loss: 7,836k).

A conditional shareholder contribution to the subsidiary GeccoDots of SEK 2,300k (5,600k) had a negative impact on the Parent Company's income statement and relates to costs for staff hired from Genovis to run the business until the operation closed on September 30, 2015. Net capital expenditure totaled SEK 858k (1,985k). Cash and cash equivalents including short-term investments totaled SEK 1,194k (5,614k) at the end of the period.

Taxes

The Parent Company has a deferred tax asset that amounted to SEK 1,718k (1,718k) at the end of the period, equivalent to a loss carryforward of about SEK 7.8m, which is expected to be utilized in the foreseeable future.

The Company's total tax loss amounts to SEK 146 million.

SUBSIDIARY GENOVIS INC.

The subsidiary Genovis Inc. handles all sales and marketing in the North American market.

SUBSIDIARY GECCODOTS AB

All activities of the subsidiary GeccoDots ended on September 30, 2015. All intangible and tangible assets have been transferred to the Parent Company, which decided to sell the intellectual property rights behind the Nanomotus project to the inventors against future royalties.

OTHER INFORMATION

Major shareholders in Genovis AB as of December 31, 2015

Name	No. of shares	Votes in %
Mikael Lönn	8,327,201	22.59
LMK Forward AB	3,654,654	9.91
Hansa Medical AB	3,641,441	9.88
Nordnet Pensionsförsäkring AB	2,393,355	6.49
Aduno AB	2,243,518	6.09
Försäkringsaktiebolaget Avanza Pension	666,162	1.81
Erik Walldén AB	639,760	1.74

Source: Euroclear Sweden AB

Related party transactions

Genovis has purchased analysis services from Redeye for a total of SEK 405k during the period. Genovis board member and principal owner Mikael Lönn, who holds a 22.59 percent stake in Genovis, owns 19.25 percent of the shares in Redeye, for which Mikael Lönn is also a board member. A guarantee fee of SEK 263,175 was paid to Mikael Lönn and relates to the guarantee entered into in connection with the rights issue with subscription period May 18 to June 1, 2015. In addition, Genovis paid interest to Mikael Lönn totaling SEK 25,767. The loan provided bridging financing at an interest rate of 5.5 percent and was repaid in 2015. In addition, in December 2015 Genovis raised loans from directors Mikael Lönn and Kenth Petersson totaling SEK 2 million at an interest rate of 5.5 percent.

Events after the end of the period

There are no significant events to report after the end of reporting period.

Outlook

Although the Life Science field is relatively independent of business cycles, periods of uncertainty can influence our customers' appetite to invest in new technology. With all development projects proceeding according to plan, Genovis is positioned to make additional advances with respect to both new products and sales. Taken together, volume growth is expected to be positive in 2016.

Risk factors

Genovis' general view of the financial risks that could affect operations has not changed since the description published in the most recent annual report. Genovis' business risks include the difficulties in retaining skilled personnel and the risk that anticipated revenue might not materialize since the Company is active in a market in which competing companies have substantially larger financial resources at their disposal. For a detailed overview of the Company's financial risks please refer to pages 50–51 in Genovis' 2014 annual report.

Annual General Meeting

The Annual General Meeting will be held on Thursday, May 12, 2016 in Lund; time and place will be announced at a later date.

Financial Calendar 2016

Interim Report	January-March	May 4
Half-Yearly Report	January - June	August 29

Annual Report

The 2015 Annual Report is expected to be available on the Genovis website www.genovis.com and at the Genovis office as of April 21, 2016.

Nomination Committee

The members of the Nomination Committee prior to the 2016 Annual General Meeting are as follows: Mikael Lönn, Hansa Medical AB represented by Göran Arvidsson, Aduno AB represented by Gunnar Bergstedt and Erik Walldén.

Proposal for dividend

The Board of Directors proposes that no dividend be paid for the 2015 financial year.

Forward-looking information

This report contains forward-looking information based on the current expectations of Group management at Genovis. Although the management believes that the expectations reflected in such forward-looking information are reasonable, no assurance can be given that such expectations will prove correct. Consequently, actual future results may vary materially from those implied in the forward-looking statements due to such changes in economic, market and competitive conditions, changes in the regulatory environment and other government actions, fluctuations in exchange rates and other factors.

Accounting policies

This interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the relevant provisions of the Swedish Annual Accounts Act. The report for the Parent Company has been prepared in accordance with chapter 9 of the Swedish Annual Accounts Act, Interim Reports. The accounting policies applied for the Group and the Parent Company are consistent with the accounting policies used in the preparation of the most recent annual report.

Consolidated statement of comprehensive income (SEK thousands)	Oct. - Dec. 2015	2014	Jan.-Dec. 2015	2014
Net sales	3,499	2,099	13,268	8,252
Other operating income	4,030	363	9,255	1,782
Raw materials and consumables	(895)	(771)	(2,459)	(3,430)
Other external expenses	(24,358)	(3,787)	(21,493)	(12,583)
Gross profit/loss	(137)	(2,096)	(1,429)	(5,979)
Personnel costs	(2,853)	(3,688)	(13,346)	(13,186)
Other operating expenses	132	3	0	(32)
Operating profit/loss before depreciation and amortization (EBITDA),	(3,858)	(5,781)	(14,775)	(19,197)
Depreciation of property, plant and equipment and amortization of intangible fixed assets	(315)	(385)	(5,049)	(1,274)
Operating profit/loss (EBIT)	(3,173)	(6,166)	(19,824)	(20,471)
Net financial items	0	23	(34)	140
Profit/loss after financial items	(3,173)	(6,143)	(19,858)	(20,331)
Taxes	111	(1,718)	(48)	(1,718)
Profit/loss after tax for the period	(3,062)	(7,861)	(19,906)	(22,049)
Other comprehensive income	(42)	0	(22)	0
Comprehensive income for the period	(3,104)	(7,861)	(19,928)	(22,049)
Attributable to shareholders in Genovis AB	(3,104)	(7,861)	(19,928)	(22,049)

Comprehensive income per share based on weighted average of the number of outstanding shares (basic and diluted)* (SEK)	(0.09)	(0.36)	(0.67)	(1.02)
---	--------	--------	--------	--------

Number of outstanding shares	Oct. - Dec.		Jan.-Dec.	
	2015	2014	2015	2014
Weighted average for the period	36,862,775	21,845,652	30,064,155	21,538,104
Number of shares at beginning of year	36,862,775	21,845,652	21,845,652	15,780,757
Number of shares at year-end	36,862,775	21,845,652	36,862,775	21,845,652
Share price at year-end, SEK	2.00	1.92	2.00	1.92

* The Company has issued 450,000 warrants. The outstanding warrants do not entail any dilution of earnings per share since a conversion to shares would result in improved reported earnings per share.

Summary Consolidated Balance Sheet
 (SEK thousands)

Dec. 31

2015 2014

Assets		
<i>Noncurrent assets</i>		
Intangible assets	2,622	5,434
Property, plant and equipment	1,765	2,307
Financial fixed assets	1,718	1,718
Current assets	8,756	4,415
Short-term investment	0	5,000
Cash and cash equivalents	2,052	688
Total assets	16,913	19,562

Equity and liabilities

Equity and liabilities		
Equity	8,822	14,583
Non-current liabilities	134	180
Current liabilities	7,957	4,799
Total equity and liabilities	16,913	19,562

Consolidated statement of changes in equity

Dec. 31

(SEK thousands)

2015 2014

Amount at start of period	14,583	33,085
New issue	14,167	3,547
Currency differential	41	0
Profit/loss for the period	(19,906)	(22,049)
Amount at end of period	8,822	14,583
Attributable to shareholders in Genovis AB	8,822	14,583

Dec. 31

Key financial ratios

2015 2014

Equity/assets ratio (%)	52	75
Equity per share at end of period* (SEK)	0.29	0.68

* Based on weighted average of the number of outstanding shares (basic and diluted)*.

Summary Consolidated statement of cash flows

(SEK thousands)	Oct. - Dec.		Jan.-Dec.	
	2015	2014	2015	2014
Cash flow from operations	(3,173)	(6,166)	(19,824)	(20,471)
Adjustment for items not affecting cash flow	273	384	5,026	1,274
Changes in working capital	(1,040)	83	(1,285)	(3,136)
Net financial items	0	23	(34)	140
Cash flow from operating activities	(3,940)	(5,676)	(16,117)	(22,193)
Investing activities	(153)	(865)	3,314	(5,043)
Cash flow after investing activities	(4,093)	(6,541)	(12,803)	(27,236)
Financing activities	0	226	0	226
Rights issue*	0	0	14,167	27,218
Cash flow for the period	(4,093)	(6,315)	1,364	208
Cash and cash equivalents at start of period	6,145	7,003	688	480
Cash and cash equivalents at end of period	2,052	688	2,052	688

Parent Company
Summary Income Statement

(SEK thousands)	Oct. - Dec.		Jan.-Dec.	
	2015	2014	2015	2014
Operating income	6,988	3,118	21,525	12,005
Operating expenses	(9,895)	(7,773)	(39,195)	(26,848)
Operating profit/loss	(2,907)	(4,655)	(17,670)	(14,843)
Net financial items	0	(1,463)	(2,330)	(5,445)
Profit/loss before tax	(2,907)	(6,118)	(20,000)	(20,288)
Deferred tax on net loss for the period	0	(1,718)	0	(1,718)
Profit/loss for the period	(2,907)	(7,836)	(20,000)	(22,006)

Summary Balance Sheet

Assets (SEK thousands)	Dec. 31	
	2015	2014
Assets		
Noncurrent assets	6,007	9,444
Current assets	8,784	4,014
Short-term investment	0	5,000
Cash and cash equivalents	1,194	614
Total assets	15,985	19,072

Equity and liabilities (SEK thousands)	Dec. 31	
	2015	2014
Equity		
Restricted equity	15,056	20,756
Non-restricted equity	(6,311)	(6,178)
Liabilities		
Current liabilities	7,240	4,494
Total equity and liabilities	15,985	19,072

Changes to shareholders' equity (SEK thousands)	Dec. 31	
	2015	2014
Amount at start of period	14,578	33,037
New issue	14,167	3,547
Profit/loss for the period	(20,000)	(22,006)
Amount at end of period	8,745	14,578
Attributable to shareholders in Genovis AB	8,745	14,578

Summary statement of cash flows
 (SEK thousands)

	Oct. - Dec. 2015	2014	Jan.-Dec. 2015	2014
Cash flow from operations	(2,907)	(4,655)	(17,671)	(14,843)
Adjustment for items not affecting cash flow	173	285	5,381	1,085
Changes in working capital	(1,275)	(410)	(277)	(2,605)
Net financial items	0	37	(30)	155
Cash flow from operating activities	(4,009)	(4,743)	(12,597)	(16,208)
Investing activities	1,506	(1,312)	(990)	(10,767)
Cash flow after investing activities	(2,503)	(6,055)	(13,587)	(26,975)
Financing activities	0	0	14,167	27,218
Cash flow for the period	(2,503)	(6,055)	580	243
Cash and cash equivalents at start of period	3,697	6,669	614	371
Cash and cash equivalents at end of period	1,194	614	1,194	614

Statement

The Board of Directors and the Chief Executive Officer certify that this year-end report provides a true and fair overview of the development of the Parent Company's and the group's business activities, financial position and results of operations as well as the significant risks and uncertainties to which the Parent Company and the companies included in the Group are exposed.

Lund February 15, 2016

Genovis AB (publ.)

On behalf of the Board of Directors Fredrik Olsson, CEO

This report has not been reviewed by the Company's auditors.

The year-end report may be ordered from the Company or downloaded at the Genovis web site:
www.genovis.com.

Genovis AB, Box 790, SE-220 07 Lund, Sweden T: +46 (0)46-10 12 30, fax: +46 (0)46-12 80 20

Contact

Fredrik Olsson, Chief Executive Officer

T: +46 (0)46-10 12 33, fredrik.olsson@genovis.com

This document is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.